Biotechnology
Medical
Cancer Prevention

Kura Oncology

$15.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-0.38%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Kura Oncology and other stocks, options, ETFs, and crypto commission-free!

About

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. Read More The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Employees
43
Headquarters
San Diego, California
Founded
2014
Market Cap
605.74M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
241.15K
High Today
$16.11
Low Today
$15.50
Open Price
$15.74
Volume
229.28K
52 Week High
$22.00
52 Week Low
$10.20

Collections

Biotechnology
Medical
Cancer Prevention
Health
Research And Development
Biopharmaceutical
Pharmaceutical
2015 IPO

News

The Motley FoolMay 8

Kura Oncology, Inc. (KURA) Q1 2019 Earnings Call Transcript

42
NasdaqMay 7

Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones

- Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track - - Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA and ICML next month - - Data from ongoing Phase 2 trial of tipifarnib in HRAS mutant HNSCC and other SCCs anticipated in second half 2019 - - $165.5 million in cash, cash equivalents and investments provide runway into 2021 - - Management to host webcast and conference call today at 4:30 p.m. ET - SAN DIE...

35

Earnings

-$0.46
-$0.42
-$0.39
-$0.35
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 5, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.